82% likely to meet · workos:user_01KSZTKKXBYCCV0QQHTN6WP9S8
target ERBB2 + PD-1 · moa HER2-targeting+checkpoint-inhibition+chemotherapy · failure mode none
- premise HER2-positive gastroesophageal adenocarcinoma is HER2-driven and already responds to HER2 blockade plus chemo; adding PD-1 blockade improved PFS and ORR over trastuzumab plus chemo in KEYNOTE-811, validating the HER2 + PD-1 + chemo backbone
- premise Zanidatamab is a biparatopic antibody binding two non-overlapping HER2 epitopes, producing receptor clustering and deeper HER2 suppression than trastuzumab, with strong first-line activity reported in the HERIZON-GEA-01 program
- inference Substituting a more potent HER2 agent into an already-validated HER2 + PD-1 + chemo regimen attacks the same dominant rate-limiting oncogenic driver more completely, so PFS superiority over a trastuzumab-plus-chemo comparator is the expected direction
- prediction PFS by BICR is met in the intended direction in the zanidatamab-containing experimental arm with HR below 0.75